Manulife (Manufacturers Life Insurance)’s Aligos Therapeutics ALGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-512
Closed -$152 3068
2021
Q4
$152 Buy
512
+21
+4% +$7.66K ﹤0.01% 2983
2021
Q3
$190K Buy
491
+48
+11% +$19K ﹤0.01% 3004
2021
Q2
$226K Buy
+443
New +$282K ﹤0.01% 3014

Other funds holding ALGS

Manulife (Manufacturers Life Insurance)'s ALGS Position: Q1 2022 in Review

Manulife (Manufacturers Life Insurance) sold out of Aligos Therapeutics (ALGS) in Q1 2022, closing a stake of 512 shares — an estimated $152 sold.

Manulife (Manufacturers Life Insurance) first reported a position in ALGS in Q2 2021 and held it in 3 quarters. The position peaked at $226K in Q2 2021. 76 funds tracked by Wall St. Rank hold ALGS as of Q1 2022.

  • Manulife (Manufacturers Life Insurance) reported no remaining Aligos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 512 Aligos Therapeutics shares in Q1 2022, an estimated $152.
  • Manulife (Manufacturers Life Insurance) first reported a position in Aligos Therapeutics in Q2 2021 and held it in 3 quarters.
  • Manulife (Manufacturers Life Insurance)'s Aligos Therapeutics position peaked at $226K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2022.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2022, filed 20 May 2022.